IE
DNTH icon

Israel Englander’s Dianthus Therapeutics DNTH Stock Holding History

Israel Englander’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.95M Sell
91,838
-170,124
-65% -$14.9M ﹤0.01% 2394
2026
Q1 		$22M Sell
261,962
-405,254
-61% -$23.5M 0.01% 1469
2025
Q4 		$27.5M Buy
667,216
+521,050
+356% +$20.2M 0.01% 1262
2025
Q3 		$5.75M Sell
146,166
-49,191
-25% -$1.26M ﹤0.01% 2990
2025
Q2 		$3.64M Buy
+195,357
New +$3.66M ﹤0.01% 3311
2025
Q1 		– Sell
-90,436
Closed -$1.97M – 5970
2024
Q4 		$1.97M Buy
90,436
+55,682
+160% +$1.43M ﹤0.01% 3659
2024
Q3 		$952K Buy
+34,754
New +$968K ﹤0.01% 4320
2024
Q2 		– Sell
-277,213
Closed -$8.32M – 6008
2024
Q1 		$8.32M Buy
277,213
+243,249
+716% +$5.29M ﹤0.01% 2365
2023
Q4 		$353K Buy
+33,964
New +$375K ﹤0.01% 4866
2023
Q1 		– Sell
-144,597
Closed -$914K – 6465
2022
Q4 		$914K Buy
144,597
+13,638
+10% +$241K ﹤0.01% 4258
2022
Q3 		$2.95M Buy
130,959
+13,747
+12% +$376K ﹤0.01% 3409
2022
Q2 		$2.25M Buy
117,212
+29,474
+34% +$728K ﹤0.01% 3586
2022
Q1 		$4.07M Buy
87,738
+45,013
+105% +$2.46M ﹤0.01% 3155
2021
Q4 		$3.03M Buy
+42,725
New +$4.29M ﹤0.01% 3374
2021
Q3 		– Sell
-4,007
Closed -$627K – 6868
2021
Q2 		$627K Buy
4,007
+1,298
+48% +$238K ﹤0.01% 5102
2021
Q1 		$513K Sell
2,709
-1,363
-33% -$229K ﹤0.01% 4805
2020
Q4 		$511K Buy
4,072
+1,739
+75% +$197K ﹤0.01% 4176
2020
Q3 		$254 Sell
2,333
-15,180
-87% -$1.8M ﹤0.01% 3942
2020
Q2 		$2.1M Buy
17,513
+2,810
+19% +$396K ﹤0.01% 2497
2020
Q1 		$1.48M Buy
14,703
+6,893
+88% +$1.28M ﹤0.01% 2227
2019
Q4 		$1.89M Buy
+7,810
New +$1.46M ﹤0.01% 2654
2018
Q3 		– Sell
-6,984
Closed -$1.51M – 3970
2018
Q2 		$1.51M Buy
+6,984
New +$1.58M ﹤0.01% 2594

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Israel Englander's DNTH Position: Q2 2026 in Review

Israel Englander reduced its Dianthus Therapeutics (DNTH) stake by 65% in Q2 2026, selling an estimated $14.9M and leaving 91,838 shares worth $8.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2394.

Israel Englander first reported a position in DNTH in Q2 2018 and has held it in 22 quarters since. The position peaked at $27.5M in Q4 2025. 267 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Israel Englander held 91,838 shares of Dianthus Therapeutics worth $8.95M as of Q2 2026.
  • Israel Englander sold 170,124 Dianthus Therapeutics shares in Q2 2026, an estimated $14.9M.
  • Dianthus Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2394 holding.
  • Israel Englander first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 22 quarters since.
  • Israel Englander's Dianthus Therapeutics position peaked at $27.5M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.